Compare Quest Diagnostics Inc (DGX) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.48B), while iShares Broad USD Investment Grade Corporate Bond trades at $49.85 (market cap $17.53B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares Broad USD Investment Grade Corporate Bond pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| DGX | USIG | |
|---|---|---|
Market Cap | $25.48B | $17.53B |
Volume | 941,866 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $247.45 | $52.69 |
52-Week Low | $173.49 | $48.54 |
Typical Hold Time | 56 Days | 44 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
USIG trades at $48.68 with minimal daily movement (+0.06%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The stock faces resistance at $49 with support at $48. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake by 0.9% in Q2 2026.
The outlook remains cautious due to bearish technicals and lack of fundamental data. Investment opportunities include institutional accumulation, but risks involve market volatility and absence of recent financial disclosures. Investors should await updated earnings reports for clearer valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
